Our COVID-19 Vaccine Study – What’s Next?
COVID-19 SCIENTIFIC RESOURCES
COVID-19 CLINICAL TRIAL RESULTS
VISIT OUR COVID-19 HUB
Cancer Screening: Get it Done
– If approved, marstacimab has potential to be a best-in-class treatment option among novel non-factor agents – Pfizer Inc. (NYSE: PFE) today announced that the first participant has been dosed in the Phase 3 BASIS study of marstacimab (PF-06741086), an anti-tissue factor pathway inhibitor (anti-TFPI) being evaluated for the treatment of people with severe hemophilia A or B, with or without inhibitors. BASIS is a global Phase 3, open-label, multicenter study that will evaluate annualized bleed…